Global Biomarker Discovery Outsourcing Services Market Size, Trend & Opportunity Analysis Report, by Type (Predictive, Safety), Therapeutic Area (Oncology, Neurology), and Forecast, 2025-2035
Global Biomarker Discovery Outsourcing Services Market Size, Opportunity Analysis and Forecast, 2025-2035
Market Definition and Introduction
The Global Biomarker Discovery Outsourcing Services Market, valued at USD 14.53 billion in 2024, is projected to soar to USD 106.00 billion by 2035, expanding at a remarkable CAGR of 19.8% during the forecast period 2025-2035. Biomarkers have become critical in early diagnosis, therapy targeting, and treatment efficacy monitoring in precision medicine. By outsourcing the biomarker discovery activity, pharmaceutical companies, biotech innovators, and research institutes can speed the timelines for research and development (R&D), lighten infrastructure burdens, and gain access to cutting-edge analytical platforms at a fraction of the expense. Today's drug development involves sophisticated biology, high bioinformatics engine capacity, and laboratory capabilities in which contract research organizations (CROs) and specialized biomarker service providers have expertise.
Consistent with regulatory authorities' emphasis on companion diagnostics and real-world evidence, biomarkers have evolved from an added-on activity to a pivotal strategic necessity in the drug development pipeline. Outsourcing also has the potential to fill capability voids, but most importantly, it brings speed of response to sponsors when it becomes necessary to shift research direction because of interim findings or newly emerging therapeutic trends. The same is true for oncology, where the driving force for personalized therapy is molecular heterogeneity: external partners are increasingly relied upon to perform multi-omics profiling, high-throughput screening, and validation studies in large and diverse patient cohorts. Neurology is also going in that direction: the unmet need is for diagnostic precision in disorders like Alzheimer's and Parkinson's, which has opened the door to demand for new biomarkers that detect pathologies even earlier and then follow disease progression more reliably.
AI and machine learning (ML) are emerging in biomarker analytics to cause a paradigm shift in the delivery model of services, which would allow the outsourced partners to integrate large-scale datasets of genomics, proteomics, and metabolomics for predictive modeling. Furthermore, the increasingly urgent demand for the global biopharma ecosystem to improve clinical trial success rates creates an even greater impetus for outsourcing biomarker discovery as a lever to better patient stratification, cost reduction, and faster market access. These factors would create the perfect environment between sponsors and service providers, wherein innovation, compliance with regulations, and speed to market would add up to a competitive advantage.
Recent Developments in the Industry
- In March 2024, Thermo Fisher Scientific unveiled an expanded biomarker discovery service suite integrating genomics, proteomics, and metabolomics, enabling pharmaceutical companies to accelerate target identification and validation. The service leverages AI-driven analytics to enhance the precision of predictive biomarkers in oncology and neurology.
- In June 2024, Charles River Laboratories entered into a collaboration with a leading biotech company to advance biomarker identification in neurodegenerative disorders. The partnership aims to streamline biomarker validation pipelines and facilitate earlier patient stratification in Alzheimer-s clinical trials.
- In January 2024, Quest Diagnostics established a global biomarker testing hub designed to support multinational clinical trials with standardized methodologies. This initiative enhances turnaround times, data consistency, and compliance with international regulatory frameworks.
Market Dynamics
The complexity in the drug development process is a capital thrust for future outsourced biomarker discovery services.
More and more, precision medicine has initiated hurdles in integration with biomarker-driven endpoints for drug developers. As a result, companies are now looking at outsourcing for the immediate availability of specialized infrastructure and domain-specific talent, as well as analytical platforms, though to minimize risk and speed up discovery timelines.
Cancer and neurology are becoming the driving forces in advancing various biomarker outsourcing engagements.
With immunotherapy now receiving more attention on cancer in addition to targeted therapies, and diagnostics becoming an essential part of treatment for neurodegenerative diseases, this has created severe specific demand for biomarker customer pipelines. CROs and niche service organizations rush in and fill those by delivering high-dimensional data analysis, bioinformatics integration, and validation across very different demographics.
The heightened interest in regulations in companion diagnostics has made biomarker discovery a concern at strategic levels.
Increasingly, regulatory authorities like the FDA and EMA are requiring drugs to have companion diagnostics when submitting them for approval, particularly for oncology drugs. In turn, this environment is increasingly pushing pharmaceutical companies to outsource biomarker discovery, ensure that drugs meet the regulatory requirements, match clinical endpoints, and therefore have these clearances faster.
The ARTAGE of AI-Driven Bioinformatics Technology Revolutionizes the Biomarker Discovery Workflow.
Innovative algorithms embedded in machine learning paired with data integration platforms can discover complex, multi-analyte biomarker signatures. Outsourcing, taking advantage of sophisticated predictive modeling tools, will offer models that have better predictive accuracy, eventually attaining better patient stratification in clinical trials.
Attractive Opportunities in the Market
- AI-Powered Biomarker Discovery - Leveraging machine learning to enhance predictive accuracy in oncology and neurology
- Companion Diagnostics Growth - Rising co-development of drugs and diagnostics driving outsourced biomarker partnerships
- Multi-Omics Integration - Comprehensive genomic, proteomic, and metabolomic profiling services gaining market traction
- Neurology Breakthroughs - Discovery of early-stage biomarkers for Alzheimer-s and Parkinson-s diagnostics
- Emerging Markets Demand - Expansion of biomarker services in APAC-s growing pharmaceutical and biotech hubs
- Regulatory Alignment - Services tailored to meet stringent FDA, EMA, and PMDA biomarker validation requirements
- Strategic Alliances - Collaborations between CROs, biopharma, and diagnostic companies for end-to-end biomarker solutions
- Clinical Trial Optimization - Biomarkers reducing trial attrition through improved patient selection and monitoring
Report Segmentation
By Type: Predictive, Safety
By Therapeutic Area: Oncology, Neurology
By Region: North America (U.S., Canada, Mexico), Europe (UK, Germany, France, Spain, Italy, Spain, Rest of Europe), Asia-Pacific (China, India, Japan, Australia, South Korea, Rest of Asia-Pacific), LAMEA (Brazil, Argentina, UAE, Saudi Arabia (KSA), Africa Rest of Latin America)
Key Market Players: Thermo Fisher Scientific, Charles River Laboratories, Eurofins Scientific, Bio-Rad Laboratories, Quest Diagnostics, Laboratory Corporation of America (LabCorp), ICON plc, Evotec AG, PPD (part of Thermo Fisher), and Medpace.
Report Aspects
Base Year: 2024
Historic Years: 2022, 2023, 2024
Forecast Period: 2025-2035
Report Pages: 292
Dominating Segments
In the biomarker discovery outsourcing market, the predictive biomarkers segment has been found to be the driver, due to the acceptance of personalized medicine.
Predictive biomarkers, in essence, predict therapeutic outcomes and inform decisions regarding targeting therapy. The high demand for predictive biomarker discovery and validation services, which are mostly outsourced, comes from the therapy area of rapidly developing
oncology trials and precision drug development for neurology.
Oncology is a prominent therapeutic area in advanced clinical trials molecular profiling requirements.
For biomarker outsourcing, oncology remains the top therapeutic area due to the complexities involved in cancer biology that necessitate extensive molecular profiling and companion diagnostic development. A growing need for specialized biomarker capabilities has been generated due to the typical acceptance of immuno-oncology drugs and targeted therapies.
The safety biomarkers segment steadily moves forward in drug development risk mitigation strategies.
Safety biomarkers, which monitor toxicity and side effects, have gained traction in various therapeutic pipelines. These outsourced partners have the advances in assays and validation systems necessary to ensure these biomarkers are effectively integrated into preclinical and clinical programs.
Key Takeaways
- Predictive Biomarker Dominance - Leading role in driving precision medicine strategies across therapeutic areas
- Oncology Focus - Largest revenue contributor due to molecular complexity and companion diagnostic requirements
- Neurology Growth - Rising need for early detection biomarkers in Alzheimer-s and Parkinson-s research
- Safety Biomarker Demand - Increasing integration into risk assessment and drug safety monitoring workflows
- AI Integration - Machine learning enhances accuracy and reduces discovery timelines
- Global Expansion - Rapid service adoption in APAC biopharma hubs
- Regulatory Influence - Compliance with biomarker validation guidelines shaping service offerings
- Strategic Collaborations - Partnerships accelerating end-to-end biomarker solution delivery
- Multi-Omics Growth - Integrated approaches delivering comprehensive disease insights
- Trial Optimization - Biomarkers improving patient selection and trial efficiency
Regional Insights
North America is at the forefront of the industry because of a very strong biopharma presence backed by state-of-the-art R&D infrastructure.
North America, by the United States, is the leading continent in the biomarker outsourcing market because of its robust and mature pharmaceutical system, a solid, well-established network of CROs, and good investment capacity into precision medicine research. The increased regulatory impetus on companion diagnostics further drives demand for the services in the region.
Europe will speed up adopting biomarker-based diagnostics, driven by regulatory strictness and innovation centers.
European countries, including the UK, Germany, and France, create an environment in which biomarker innovation is enhanced by clustering research, government-public partnership, and strict adherence to EMA requirements. These features make Europe a leader in the uptake of high-rated biomarker outsourcing services.
Asia-Pacific is the fastest expanding region owing to ever-increasing biopharma growth and clinical trial activities.
China, India, and South Korea are witnessing a phenomenal increase in biomarker outsourcing demand, mainly driven by their booming pharmaceutical manufacturing, increasing participation in clinical trials, and government incentives to spur biotech innovation. Also increasing the growth prospect is a cost-efficient yet technologically advanced CRO landscape in the APAC region.
Key Benefits for Stakeholders
- The report offers a quantitative assessment of market segments, emerging trends, projections, and market dynamics for the period 2024 to 2035.
- The report presents comprehensive market research, including insights into key growth drivers, challenges, and potential opportunities.
- Porter's Five Forces analysis evaluates the influence of buyers and suppliers, helping stakeholders make strategic, profit-driven decisions and strengthen their supplier-buyer relationships.
- A detailed examination of market segmentation helps identify existing and emerging opportunities.
- Key countries within each region are analysed based on their revenue contributions to the overall market.
- The positioning of market players enables effective benchmarking and provides clarity on their current standing within the industry.
- The report covers regional and global market trends, major players, key segments, application areas, and strategies for market expansion.
Frequently Asked Question(FAQ) :
Oncology is the leading therapeutic area. This dominance is driven by the molecular heterogeneity of cancer, the rise of immuno-oncology, and the increasing regulatory requirement for companion diagnostics to support targeted therapies.
Outsourcing allows sponsors to accelerate R&D timelines, reduce heavy infrastructure costs, and access specialized expertise in bioinformatics and high-throughput screening. It also provides the flexibility to shift research directions quickly based on interim clinical findings.
AI and ML are causing a paradigm shift by enabling the integration of massive datasets across genomics, proteomics, and metabolomics. These technologies allow outsourced partners to develop predictive models with higher accuracy, improving patient stratification in clinical trials.
Predictive biomarkers are the primary market driver as they help predict therapeutic outcomes and inform decisions on targeted therapies. Safety biomarkers are used for risk mitigation, helping developers monitor toxicity and side effects during preclinical and clinical programs.
North America, led by the United States, is the dominant region. Its leadership is attributed to a mature pharmaceutical ecosystem, a well-established network of Contract Research Organizations (CROs), high investment in precision medicine, and a strong regulatory focus on companion diagnostics.
The Asia-Pacific (APAC) region is the fastest-growing market. Growth is fueled by booming pharmaceutical manufacturing in China and India, increasing participation in global clinical trials, and government incentives designed to spur biotech innovation.
Regulatory bodies are increasingly requiring drugs—particularly in oncology—to be submitted alongside companion diagnostics. This strategic necessity pushes pharmaceutical companies to seek outsourced expertise to ensure compliance and achieve faster market clearance.
In 2024, Thermo Fisher Scientific expanded its multi-omics service suite; Charles River Laboratories collaborated with a major biotech firm to advance neurodegenerative biomarkers; and Quest Diagnostics established a global biomarker testing hub to standardize methodologies for multinational trials.
Significant opportunities include the development of AI-powered discovery platforms, the discovery of early-stage biomarkers for neurology (Alzheimer’s and Parkinson’s), the integration of multi-omics profiling, and the expansion of services into emerging APAC biopharma hubs.
